We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session

Sunday
May 08
10:30 - 11:30
Poster Station 2
12: GI
Pierfrancesco Franco, Italy
Poster Discussions are presented at one of the sessions scheduled at the two poster terminals in the exhibition. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will not be streamed but authors are invited to upload per-recordings for the online platform.
2310
Poster Discussion
Clinical
A PET/CT-based radiomic signature as a predictor of early progression in LA-Pancreatic Cancer
Michele Fiore, Italy
PD-0492
Acute toxicity of short course radiotherapy with prolonged interval to surgery for rectal cancer
Maaike Verweij, The Netherlands
PD-0493
Secondary dosimetric analysis of a phase II study on radiation volume de-escalation in rectal cancer
Gabriele D'Ercole, Italy
PD-0494
Stereotactic MR-guided Adaptive RT for rectal cancer: toxicity, radiological & pathological response
Alessandra Castelluccia, Italy
PD-0495
Downstaging as an early predictor in rectal cancer: results of a pooled dataset of 4167 patients
Giuditta Chiloiro, Italy
PD-0496
Atlas-based auto-segmentation of pelvic CTVs in FDG-PET-CT planning of anal cancer
Marciana Nona Duma, Germany
PD-0498
Bonesparing radiotherapy for anal cancer. -Initial planning quality for the DACG II trial
Camilla Kronborg, Denmark
PD-0499
Outcomes and hemato-immunological toxicity in anal cancer patients with or without HIV infection
Christian Velten, USA
PD-0500
Stereotactic MR guided online adaptive radiotherapy for abdominal and pelvic lymph node metastases
Kasia Owczarczyk, United Kingdom
PD-0502
BELOW PRESENTATIONS AVAILABLE VIA ONLINE PLATFORM
Prognostic role of GLUT-1 in locally advanced rectal cancer
Changhoon Song, Korea Republic of
PD-0497
Patterns of failure in anal cancer after IMRT and chemotherapy: Impact of 1 vs 2 doses of Mitomycin.
Zainab Al Habsi, Canada
PD-0501